Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Depreciation and Depletion (2016 - 2025)

Alterity Therapeutics has reported Depreciation and Depletion over the past 4 years, most recently at -$10527.8 for Q4 2018.

  • For Q4 2018, Depreciation and Depletion fell 46.8% year-over-year to -$10527.8; the TTM value through Dec 2018 reached -$1512.2, down 108.4%, while the annual FY2025 figure was $18346.6, 20.85% down from the prior year.
  • Depreciation and Depletion for Q4 2018 was -$10527.8 at Alterity Therapeutics, down from $165.03 in the prior quarter.
  • Over five years, Depreciation and Depletion peaked at $17032.3 in Q2 2016 and troughed at -$10527.8 in Q4 2018.
  • A 4-year average of $2402.5 and a median of $165.03 in 2018 define the central range for Depreciation and Depletion.
  • Biggest five-year swings in Depreciation and Depletion: crashed 185.88% in 2016 and later increased 9.09% in 2017.
  • Year by year, Depreciation and Depletion stood at $9186.1 in 2015, then tumbled by 185.88% to -$7888.7 in 2016, then increased by 9.09% to -$7171.3 in 2017, then crashed by 46.8% to -$10527.8 in 2018.
  • Business Quant data shows Depreciation and Depletion for ATHE at -$10527.8 in Q4 2018, $165.03 in Q2 2018, and -$7171.3 in Q4 2017.